Sandoz to begin Phase III trial of aflibercept biosimilar
By EsqSocial Corporation 07/05/21
On May 3, 2021, Sandoz announced that it will begin enrolling patients in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study for its proposed biosimilar to Regeneron’s EYLEA (aflibercept) product. EYLEA is indicated for neovascular age-related macular degeneration (nAMD), diabetic macular oedema, macular oedema secondary to retinal vein occlusion, and other neovascular retinal diseases....
By: Goodwin